# Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

> **NCT00536861** · PHASE1 · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 11 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00536861
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2008-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536861, "Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00536861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*